| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
ALX Oncology Holdings Inc.
13D/A
Amendment 2
ALXO · 00166B105
|
10.0% |
10/16/2026
Event 10/14/2026
|
|||
| venBio Global Strategic Fund, L.P. | 3.3% | ||||
| venBio Global Strategic Fund II L.P. | 6.5% | ||||
| venBio Global Strategic GP, L.P. | 3.3% | ||||
| venBio Global Strategic GP II, L.P. | 6.5% | ||||
| venBio Global Strategic GP, Ltd. | 3.3% | ||||
| venBio Global Strategic GP II, Ltd. | 6.5% | ||||
| Goodman Corey S | 10.0% | ||||
|
ALX Oncology Holdings Inc.
13D/A
Amendment 1
ALXO · 00166B105
|
10.0% |
2/4/2026
Event 2/2/2026
|
|||
| venBio Global Strategic Fund, L.P. | 3.4% | ||||
| venBio Global Strategic Fund II L.P. | 6.4% | ||||
| venBio Global Strategic GP, L.P. | 3.4% | ||||
| venBio Global Strategic GP II, L.P. | 6.4% | ||||
| venBio Global Strategic GP, Ltd. | 3.4% | ||||
| venBio Global Strategic GP II, Ltd. | 6.4% | ||||
| Adelman Robert J | 9.9% | ||||
| Goodman Corey S | 10.0% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.